Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/angiogenesis-inhibition-hypoxia-and-targeting-the-bone-marrow-CjT5GcUYoA
References (38)
-
A. Azab, J. Runnels, C. Pitsillides, A. Moreau, F. Azab, X. Leleu, X. Jia, R. Wright, Beatriz Ospina, Alicia Carlson, C. Alt, N. Burwick, A. Roccaro, H. Ngo, M. Farag, Molly Melhem, A. Sacco, N. Munshi, T. Hideshima, B. Rollins, K. Anderson, A. Kung, Charles Lin, I. Ghobrial (2009)
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.Blood, 113 18
-
C. Mitsiades, E. Ocio, A. Pandiella, P. Maiso, C. Gajate, M. Garayoa, D. Vilanova, J. Montero, N. Mitsiades, C. McMullan, N. Munshi, T. Hideshima, D. Chauhan, P. Avilés, G. Otero, G. Faircloth, M. Mateos, P. Richardson, F. Mollinedo, J. San-Miguel, K. Anderson (2008)
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.Cancer research, 68 13
-
A. Azab, Jinsong Hu, Phong Quang, F. Azab, C. Pitsillides, R. Awwad, B. Thompson, P. Maiso, Jessica Sun, C. Hart, A. Roccaro, A. Sacco, H. Ngo, Charles Lin, A. Kung, Ruben Carrasco, K. Vanderkerken, I. Ghobrial (2011)
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.Blood, 119 24
-
C. Kibler, F. Schermutzki, H. Waller, R. Timpl, C. Müller, G. Klein (1998)
Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules.Cell adhesion and communication, 5 4
-
Martha Raschko, S. Markovina, S. Miyamoto, W. Longo, E. Williams, T. McFarland, J. Werndli, E. Wagner, M. Juckett, N. Callander (2007)
Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).Blood, 110
-
J. Caers, E. Menu, H. Raeve, D. Lepage, E. Valckenborgh, B. Camp, E. Álvarez, K. Vanderkerken (2008)
Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myelomaBritish Journal of Cancer, 98
-
Matthew Strobeck (2007)
Multiple myeloma therapiesNature Reviews Drug Discovery, 6
-
Santhosh Kumar, T. Witzig, A. Dispenzieri, M. Lacy, L. Wellik, R. Fonseca, J. Lust, M. Gertz, R. Kyle, P. Greipp, S. Rajkumar (2004)
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myelomaLeukemia, 18
-
R. Lozano, M. Naghavi, Kyle Foreman, S. Lim, K. Shibuya, V. Aboyans, J. Abraham, T. Adair, Rakesh Aggarwal, S. Ahn, Mohammad Almazroa, Miriam Alvarado, H. Anderson, Laurie Anderson, Kathryn Andrews, C. Atkinson, L. Baddour, S. Barker-Collo, D. Bartels, Michelle Bell, Emelia Benjamin, D. Bennett, K. Bhalla, B. Bikbov, A. Abdulhak, G. Birbeck, F. Blyth, I. Bolliger, S. Boufous, C. Bucello, M. Burch, P. Burney, J. Carapetis, Honglei Chen, David Chou, S. Chugh, L.E. Coffeng, S. Colan, Samantha Colquhoun, K. Colson, J. Condon, M. Connor, Leslie Cooper, M. Corriere, Monica Cortinovis, Karen Vaccaro, W. Couser, Benjamin Cowie, M. Criqui, M. Cross, Kaustubh Dabhadkar, N. Dahodwala, D. Leo, L. Degenhardt, A. Delossantos, J. Denenberg, D. Jarlais, S. Dharmaratne, E. Dorsey, T. Driscoll, H. Duber, Beth Ebel, P. Erwin, Patricia Espindola, M. Ezzati, V. Feigin, A. Flaxman, M. Forouzanfar, F. Fowkes, R. Franklin, M. Fransen, Michael Freeman, S. Gabriel, E. Gakidou, F. Gaspari, R. Gillum, D. González-Medina, Y. Halasa, D. Haring, James Harrison, Rasmus Havmoeller, Roderick Hay, B. Hoen, Peter Hotez, D. Hoy, K. Jacobsen, S. James, Rashmi Jasrasaria, S. Jayaraman, N. Johns, G. Karthikeyan, N. Kassebaum, A. Keren, J. Khoo, L. Knowlton, O. Kobusingye, A. Koranteng, R. Krishnamurthi, M. Lipnick, S. Lipshultz, Summer Ohno, J. Mabweijano, Michael MacIntyre, Leslie Mallinger, L. March, Guy Marks, Robert Marks, A. Matsumori, R. Matzopoulos, B. Mayosi, J. Mcanulty, M. McDermott, J. Mcgrath, Ziad Memish, G. Mensah, T. Merriman, C. Michaud, Matthew Miller, Ted Miller, C. Mock, A. Mocumbi, A. Mokdad, Andrew Moran, K. Mulholland, M. Nair, L. Naldi, K. Narayan, K. Nasseri, P. Norman, Martin O'Donnell, Saad Omer, K. Ortblad, Richard Osborne, D. Ozgediz, B. Pahari, J. Pandian, A. Rivero, R. Padilla, F. Pérez-Ruiz, N. Perico, D. Phillips, Kelsey Pierce, C. Pope, E. Porrini, F. Pourmalek, M. Raju, D. Ranganathan, Jürgen Rehm, David Rein, G. Remuzzi, F. Rivara, Thomas Roberts, Felipe León, Lisa Rosenfeld, L. Rushton, Ralph Sacco, Joshua Salomon, Uchechukwu Sampson, Ella Sanman, D. Schwebel, M. Seguí-Gómez, Donald Shepard, David Singh, J. Singleton, K. Sliwa, Emma Smith, A. Steer, Jennifer Taylor, Bernadette Thomas, I. Tleyjeh, J. Towbin, T. Truelsen, E. Undurraga, N. Venketasubramanian, L. Vijayakumar, T. Vos, Gregory Wagner, Mengru Wang, Wenzhi Wang, K. Watt, Martin Weinstock, R. Weintraub, J. Wilkinson, A. Woolf, S. Wulf, P. Yeh, Paul Yip, A. Zabetian, Zhi‐Jie Zheng, A. Lopez, C. Murray (2012)
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 380
-
I. Ghobrial, J. Laubach, K. Shain, R. Baz, Erica Boswell, P. Henrick, A. Azab, Courtney Hanlon, S. Chuma, H. Leblebjian, Kimberly Noonan, Megan MacNabb, D. Warren, P. Armand, Claudia Paba-Prada, N. Munshi, R. Schlossman, K. Anderson, P. Richardson (2010)
Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple MyelomaBlood, 116
-
K. Podar, L. Catley, Y. Tai, R. Shringarpure, P. Carvalho, Toshiaki Hayashi, R. Burger, R. Schlossman, P. Richardson, L. Pandite, Rakesh Kumar, T. Hideshima, D. Chauhan, K. Anderson (2004)
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.Blood, 103 9
-
P. Storti, M. Bolzoni, G. Donofrio, I. Airoldi, D. Guasco, D. Toscani, E. Martella, M. Lazzaretti, C. Mancini, L. Agnelli, K. Patrene, S. Maïga, V. Franceschi, S. Colla, J. Anderson, A. Neri, M. Amiot, F. Aversa, G. Roodman, N. Giuliani (2013)
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destructionLeukemia, 27
-
M. Meter, Edward Kim (2010)
Bevacizumab: current updates in treatmentCurrent Opinion in Oncology, 22
-
J. Fowler, G. Mundy, S. Lwin, C. Edwards (2012)
Bone Marrow Stromal Cells Create a Permissive Microenvironment for Myeloma Development : A New Stromal Role for Wnt Inhibitor Dkk 1 -
H. Prince, D. Hönemann, A. Spencer, D. Rizzieri, E. Stadtmauer, A. Roberts, N. Bahlis, G. Tricot, Bill Bell, D. Demarini, A. Suttle, K. Baker, L. Pandite (2009)
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).Blood, 113 19
-
M. Zangari, E. Anaissie, A. Stopeck, Alyssa Morimoto, Nguyen Tan, J. Lancet, M. Cooper, A. Hannah, G. Garcia-Manero, S. Faderl, H. Kantarjian, J. Cherrington, M. Albitar, F. Giles (2004)
Phase II Study of SU 5416 , a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor , in Patients with Refractory Multiple Myeloma -
S. Rajkumar, G. Gahrton, P. Bergsagel (2011)
Approach to the treatment of multiple myeloma: a clash of philosophies.Blood, 118 12
-
G. Somlo, A. Lashkari, W. Bellamy, T. Zimmerman, J. Tuscano, M. O'donnell, A. Mohrbacher, S. Forman, P. Frankel, Helen Chen, J. Doroshow, D. Gandara (2011)
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trialBritish Journal of Haematology, 154
-
J. Fowler, G. Mundy, S. Lwin, C. Edwards (2012)
Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.Cancer research, 72 9
-
Y. Alsayed, H. Ngo, J. Runnels, X. Leleu, U. Singha, C. Pitsillides, J. Spencer, T. Kimlinger, Joanne Ghobrial, X. Jia, G. Lu, M. Timm, Ashok Kumar, D. Côté, I. Veilleux, K. Hedin, G. Roodman, T. Witzig, A. Kung, T. Hideshima, K. Anderson, Charles Lin, I. Ghobrial (2007)
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.Blood, 109 7
-
A. Romano, C. Conticello, M. Cavalli, C. Vetro, Alessia Fauci, N. Parrinello, F. Raimondo (2014)
Immunological Dysregulation in Multiple Myeloma MicroenvironmentBioMed Research International, 2014
-
P. Liebisch, S. Eppinger, Christine Schöpflin, G. Stehle, G. Munzert, H. Döhner, M. Schmid (2005)
CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.Haematologica, 90 4
-
A. Azab, Phong Quang, F. Azab, C. Pitsillides, B. Thompson, T. Chonghaile, J. Patton, P. Maiso, V. Monrose, A. Sacco, H. Ngo, L. Flores, Charles Lin, J. Magnani, A. Kung, A. Letai, Ruben Carrasco, A. Roccaro, I. Ghobrial (2012)
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.Blood, 119 6
-
R. Ria, I. Catacchio, S. Berardi, A. Luisi, A. Caivano, C. Piccoli, V. Ruggieri, M. Frassanito, D. Ribatti, B. Nico, T. Annese, S. Ruggieri, A. Guarini, C. Minoia, P. Ditonno, E. Angelucci, D. Derudas, M. Moschetta, F. Dammacco, A. Vacca (2013)
HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic TargetClinical Cancer Research, 20
-
M. Kovacs, D. Reece, D. Marcellus, R. Meyer, S. Mathews, R. Dong, E. Eisenhauer (2006)
A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145Investigational New Drugs, 24
-
M. Zangari, E. Anaissie, A. Stopeck, Alyssa Morimoto, Nguyen Tan, J. Lancet, M. Cooper, A. Hannah, G. Garcia-Manero, S. Faderl, H. Kantarjian, J. Cherrington, M. Albitar, F. Giles (2004)
Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple MyelomaClinical Cancer Research, 10
-
A. Roccaro, T. Hideshima, N. Raje, Shaji Kumar, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Ribatti, B. Nico, A. Vacca, F. Dammacco, P. Richardson, K. Anderson (2006)
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.Cancer research, 66 1
-
F. Raimondo, M. Azzaro, Giuseppe, A., Palumbo, S. Bagnato, G. Giustolisi, Pietro, M., Floridia, Grazia Sortino (2000)
Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.Haematologica, 85 8
-
E. Deryugina, J. Quigley (2008)
Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasisHistochemistry and Cell Biology, 130
-
P. Puente, B. Muz, F. Azab, A. Azab (2013)
Cell Trafficking of Endothelial Progenitor Cells in Tumor ProgressionClinical Cancer Research, 19
-
Wenlin Du, Y. Hattori, A. Hashiguchi, K. Kondoh, N. Hozumi, Y. Ikeda, M. Sakamoto, J. Hata, Taketo Yamada (2004)
Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatmentPathology International, 54
-
V. Kotla, Swati Goel, Sangeeta Nischal, Christoph Heuck, Kumar Vivek, Bhaskar Das, Amit Verma (2009)
Mechanism of action of lenalidomide in hematological malignanciesJournal of Hematology & Oncology, 2
-
M. Broggini, S. Marchini, E. Galliera, Patrizia Borsotti, G. Taraboletti, E. Erba, M. Sironi, J. Jimeno, G. Faircloth, R. Giavazzi, M. D’Incalci (2003)
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4Leukemia, 17
-
H. Ludwig, K. Weisel, M. Engelhardt, R. Greil, A. Cafro, M. Petrucci, T. Dümmler, S. Zöllner, S. Zeitler, K. Riecke, A. Kruschinski (2013)
Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase IIa StudyBlood, 122
-
Shaji Kumar, A. Dispenzieri, M. Lacy, M. Gertz, F. Buadi, Shivlal Pandey, P. Kapoor, D. Dingli, S. Hayman, N. Leung, J. Lust, A. McCurdy, S. Russell, S. Zeldenrust, R. Kyle, S. Rajkumar, Shaji Kumar (2013)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia, 28
-
A. Vacca, D. Ribatti (2006)
Bone marrow angiogenesis in multiple myelomaLeukemia, 20
-
J. Kern, G. Untergasser, C. Zenzmaier, B. Sarg, G. Gastl, E. Gunsilius, M. Steurer (2009)
GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib.Blood, 114 18
-
D. Ribatti, A. Vacca (2008)
The role of microenvironment in tumor angiogenesisGenes & Nutrition, 3
- Publisher
- Springer Journals
- Copyright
- Copyright © 2014 by Springer-Verlag Wien
- Subject
- Medicine & Public Health; Oncology; Medicine/Public Health, general
- ISSN
- 1865-5041
- eISSN
- 1865-5076
- DOI
- 10.1007/s12254-014-0184-2
- Publisher site
- See Article on Publisher Site
Abstract
Multiple myeloma (MM) is a hematological B-cell malignancy that has still a fatal prognosis. Although the treatments have improved, one major problem in MM is the clinical resistance to available drugs and combination therapies over time. Novel agents, such as oral proteasome inhibitors, monoclonal antibodies, second generation immunomodulatory drugs and therapies targeting the cell signaling and the tumor microenvironment are in development for the treatment of relapsed/refractory MM. In this review, we refer on the role of new strategies targeting the tumor microenvironment, especially on angiogenesis, hypoxia and other interactions between MM and bone marrow components.
Journal
memo - Magazine of European Medical Oncology – Springer Journals
Published: Nov 13, 2014